
    
      The present study is designed as a prospective, open-label, multicentre, phase I/III study
      investigating the 14 day single-dose pharmacokinetic properties, efficacy and safety of BT524
      following intravenous administration in the treatment or prophylaxis of bleeding in patients
      with congenital afibrinogenemia or severe congenital hypofibrinogenemia.
    
  